Cargando…
Part 5: Myelodysplastic syndromes—Treatment of high-risk disease
Autores principales: | Magalhães, Silvia Maria Meira, Chauffaille, Maria de Lourdes Lopes Ferrari, Velloso, Elvira Deolinda Rodrigues Pereira, Buzzini, Renata, Bernardo, Wanderley Marques |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Sociedade Brasileira de Hematologia e Hemoterapia
2018
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6098179/ https://www.ncbi.nlm.nih.gov/pubmed/30128439 http://dx.doi.org/10.1016/j.htct.2018.05.013 |
Ejemplares similares
-
Part 3: Myelodysplastic syndromes—Treatment of low-risk patients without the 5q deletion
por: Velloso, Elvira Deolinda Rodrigues Pereira, et al.
Publicado: (2018) -
Part 4: Myelodysplastic syndromes—Treatment of low-risk patients with the 5q deletion
por: Magalhães, Silvia Maria Meira, et al.
Publicado: (2018) -
Guidelines on myelodysplastic syndromes: Associação Brasileira de Hematologia, Hemoterapia e Terapia Celular
por: Magalhães, Silvia Maria Meira, et al.
Publicado: (2018) -
Part 2: Myelodysplastic syndromes – classification systems
por: Lorand-Metze, Irene, et al.
Publicado: (2018) -
Scientific comment on tumor suppressor p53 protein expression: prognostic significance in patients with low-risk myelodysplastic syndrome
por: Velloso, Elvira Deolinda Rodrigues Pereira
Publicado: (2014)